Johnson & Johnson to Host Pharmaceutical Business Review

NEW BRUNSWICK, N.J., April 20, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceutical business for the investment community beginning at 8:30 a.m. (Eastern Time) on Wednesday, May 20, 2015 at the Hyatt Regency Hotel in New Brunswick, New Jersey and ending at approximately 3:00 p.m.

Paul Stoffels, M.D., Worldwide Chairman Pharmaceuticals, and Chief Scientific Officer and Joaquin Duato, Worldwide Chairman, Pharmaceuticals will host the meeting. Dominic Caruso, Vice President, Finance and Chief Financial Officer will provide opening remarks.  The meeting will feature presentations from the therapeutic area leaders within the Pharmaceutical Research and Development organization.

The agenda for the day will be posted on the Investor Relations website on approximately May 13th.

Investors and other interested parties may access this meeting by visiting the Company's website at www.investor.jnj.com for a simultaneous webcast of the presentations. 

A replay and podcast will be available shortly after the live webcast through www.investor.jnj.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-to-host-pharmaceutical-business-review-300068667.html

SOURCE Johnson & Johnson

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.